Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05436093
NA
CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Sponsor: Peking University Cancer Hospital & Institute
View on ClinicalTrials.gov
Summary
The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2022-06-23
Completion Date
2027-12
Last Updated
2026-03-04
Healthy Volunteers
No
Conditions
Interventions
DRUG
18F-FDG
All study participants will undergo one 18F-FDG PET/CT scan.
Locations (1)
Beijing cancer hospital
Beijing, Beijing Municipality, China